Literature DB >> 10832831

Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Breast Cancer Progression Working Party.

.   

Abstract

We have reported that angiogenic primary breast carcinoma can relapse not only as angiogenic, but also as non-angiogenic, lung metastases. This non-angiogenic pathway seems to be a novel pathway of cancer progression, and such tumours are likely to be resistant to antiangogenic treatment.

Entities:  

Mesh：

Year:  2000        PMID： 10832831

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  26 in total

1.  Evidence Showing That Tumors Can Grow Without Angiogenesis and Can Switch Between Angiogenic and Nonangiogenic Phenotypes.

Authors:  Francesco Pezzella; Kevin C Gatter
Journal:  J Natl Cancer Inst       Date:  2016-04-08       Impact factor: 13.506

Review 2.  Non-angiogenic tumours and their influence on cancer biology.

Authors:  Tom Donnem; Andrew R Reynolds; Elizabeth A Kuczynski; Kevin Gatter; Peter B Vermeulen; Robert S Kerbel; Adrian L Harris; Francesco Pezzella
Journal:  Nat Rev Cancer       Date:  2018-03-09       Impact factor: 60.716

3.  Molecular determinants of ovarian cancer plasticity.

Authors:  A K Sood; E A Seftor; M S Fletcher; L M Gardner; P M Heidger; R E Buller; R E Seftor; M J Hendrix
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

Review 4.  Vascular mimicry: Triggers, molecular interactions and in vivo models.

Authors:  Stephen L Wechman; Luni Emdad; Devanand Sarkar; Swadesh K Das; Paul B Fisher
Journal:  Adv Cancer Res       Date:  2020-07-16       Impact factor: 6.242

Review 5.  Evading anti-angiogenic therapy: resistance to anti-angiogenic therapy in solid tumors.

Authors:  Nandini Dey; Pradip De; Leyland-Jones Brian
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 6.  Histopathological growth patterns of liver metastasis: updated consensus guidelines for pattern scoring, perspectives and recent mechanistic insights.

Authors:  Emily Latacz; Diederik Höppener; Ali Bohlok; Vincent Donckier; Peter M Siegel; Raymond Barnhill; Marco Gerling; Cornelis Verhoef; Peter B Vermeulen; Sophia Leduc; Sébastien Tabariès; Carlos Fernández Moro; Claire Lugassy; Hanna Nyström; Béla Bozóky; Giuseppe Floris; Natalie Geyer; Pnina Brodt; Laura Llado; Laura Van Mileghem; Maxim De Schepper; Ali W Majeed; Anthoula Lazaris; Piet Dirix; Qianni Zhang; Stéphanie K Petrillo; Sophie Vankerckhove; Ines Joye; Yannick Meyer; Alexander Gregorieff; Nuria Ruiz Roig; Fernando Vidal-Vanaclocha; Larsimont Denis; Rui Caetano Oliveira; Peter Metrakos; Dirk J Grünhagen; Iris D Nagtegaal; David G Mollevi; William R Jarnagin; Michael I D'Angelica; Andrew R Reynolds; Michail Doukas; Christine Desmedt; Luc Dirix
Journal:  Br J Cancer       Date:  2022-06-01       Impact factor: 9.075

Review 7.  Tumor cell vascular mimicry: Novel targeting opportunity in melanoma.

Authors:  Mary J C Hendrix; Elisabeth A Seftor; Richard E B Seftor; Jun-Tzu Chao; Du-Shieng Chien; Yi-Wen Chu
Journal:  Pharmacol Ther       Date:  2016-01-22       Impact factor: 12.310

8.  Analysis of neovasculature in uveal melanoma by targeting the TGFbeta-binding receptor endoglin: is there prognostic relevance of proliferating endothelium?

Authors:  Focke Ziemssen; Rayime Wegner; Jürgen Wegner; Olcay Tatar; Daniela Süsskind; Faik Gelisken; Martin Rohrbach; Karl U Bartz-Schmidt; Salvatore Grisanti
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-08       Impact factor: 3.117

Review 9.  Models and molecular mechanisms of blood vessel co-option by cancer cells.

Authors:  Yu Zhang; Sarah Wang; Andrew C Dudley
Journal:  Angiogenesis       Date:  2019-10-18       Impact factor: 9.596

10.  Is nonangiogenesis a novel pathway for cancer progression? A study using 3-dimensional tumour reconstructions.

Authors:  O Adighibe; K Micklem; L Campo; M Ferguson; A Harris; R Pozos; K Gatter; F Pezzella
Journal:  Br J Cancer       Date:  2006-04-24       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.